|
SLC38A6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.27829999918561E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.91899999949052E-07 |
| Normal-vs-Stage2 |
1.82067999999758E-05 |
| Normal-vs-Stage3 |
5.58840000053351E-07 |
| Normal-vs-Stage4 |
2.23729999970779E-07 |
| Stage1-vs-Stage2 |
4.591400E-01 |
| Stage1-vs-Stage3 |
3.823000E-01 |
| Stage1-vs-Stage4 |
8.894100E-02 |
| Stage2-vs-Stage3 |
9.471200E-01 |
| Stage2-vs-Stage4 |
4.485200E-01 |
| Stage3-vs-Stage4 |
3.754800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5037999956391E-08 |
| Normal-vs-AfricanAmerican |
2.205200E-01 |
| Normal-vs-Asian |
3.044300E-03 |
| Caucasian-vs-AfricanAmerican |
3.278200E-01 |
| Caucasian-vs-Asian |
2.934000E-01 |
| AfricanAmerican-vs-Asian |
6.725400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.96599999957981E-07 |
| Normal-vs-Female |
2.45329999648547E-08 |
| Male-vs-Female |
8.251200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.0540000000846E-07 |
| Normal-vs-Age(41-60Yrs) |
2.08739999951746E-07 |
| Normal-vs-Age(61-80Yrs) |
2.40190000000418E-06 |
| Normal-vs-Age(81-100Yrs) |
1.308250E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.874400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.108400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.024800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.031200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.036200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.796400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.117690E-03 |
| Classical-VS-Follicular |
4.205600E-01 |
| Classical-VS-Other |
3.811600E-01 |
| Classical-VS-Normal |
2.94540000000953E-06 |
| Tall-VS-Follicular |
2.322300E-02 |
| Tall-VS-Other |
6.068000E-01 |
| Tall-VS-Normal |
5.5380999786081E-09 |
| Follicular-VS-Other |
4.569800E-01 |
| Follicular-VS-Normal |
2.86240000002547E-06 |
| Other-VS-Normal |
3.617000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.40250000016884E-07 |
| Normal-vs-N1 |
3.64309999945078E-07 |
| N0-vs-N1 |
2.223600E-01 |
|
|
